Return to homepagePandemic Pact

Targeting the deubiquitinase activity of Coronaviruses: the VirDUB programme

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85471

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $800,902.72

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    Walter and Eliza Hall Institute of Medical Research

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SARS-CoV-2 shares mechanisms to efficiently reproduce and infect human cells with previous coronaviruses. We propose to directly drug a viral enzyme, the Papain-like protease PLpro, required for this process. During Stage 1, the VirDUB progam will deploy an accelerated approach to identify potent drugs disabling PLpro. During Stage 2, candidate antivirals will progress through already established clinical trials to offer benefit to patients and health professional for prophylaxis and treatment.